Regenerative Medicine Scientist Speaks about Arthritis at A4M

Rafael Gonzalez, PhD, the head of Research and Development Department and a staff member of Rehealth, was invited to present at the American Academy of Anti-Aging Medicine Conference in Orlando on May 17, 2014. With over 12 years of experience, Dr. Gonzalez has become a key opinion leader in the biomedical industry and has expansive knowledge on the behavior of stem cells and stem cell-based regenerative medicine in arthritis. His research includes clinical stem cell applications for multiple diseases,  degenerative disorders and research on the behavior of stem cell cultures and cell biology from several development stages.

The American Academy of Anti-Aging Medicine, also known as A4M, is a well respected non-profit organization that is dedicated to the advancement of technology in detecting, preventing and treating aging related diseases and promoting research in the aging process.  A4M holds one of the largest conferences bi-annually on anti-aging, and regenerative and aesthetic medicine. This year, Dr. Gonzalez was afforded  the opportunity to present as a key note speaker on the use of mesenchymal stem cells in the treatment of arthritis. Below is an abstract of his presentation.

Mesenchymal Stem Cells for the Treatment of Arthritis:  Translation From Clinical Research to Standard of Care in Clinical Practice

According to the World Health Organization (WHO), musculoskeletal disease is the most common cause of severe long-term pain and disability. The Centers for Disease Control (CDC), reports one in five adults in the United States  having doctor-diagnosed arthritis.  By 2030, an estimated 67 million Americans ages 18 years or older are projected to have doctor-diagnosed arthritis.  Current treatments for these conditions are limited in that they merely treat the symptoms of the condition, rather than addressing prevention or cure.  Additionally, many systemic remedies have undesirable gastrointestinal, renal, hepatic, and cardiac side effects.

Both osteoarthritis and rheumatoid arthritis both possess inflammatory and immunological involvement, which makes treatment confounding.  Mesenchymal stem cells are non-hematopoietic progenitor cells isolated from adult tissues that possess immunosuppression and anti-inflammatory effects.  Mesenchymal stem cells possess the ability to differentiate into osteoblasts (bone), adipocytes (fat), and chrondrocytes (cartilage).  Additionally, they aid in tissue regeneration in two ways.  First, mesenchymal cells secrete growth factors (transforming growth factor-beta, insulin-like growth factors, fibroblast growth factors, platelet-derived growth factors, and Wnts), which exert trophic effects on surrounding cells.  Second, they have the ability to coordinate tandem differentiation with differentiated and undifferentiated host cells.  These combined characteristics make mesenchymal stem cells an attractive therapeutic option for the treatment of arthritis.

The purpose of this presentation is to translate the research literature, protocols, and procedures into reproducible results that can be used in-office to effectively treat arthritic conditions.  A comprehensive review of the literature and research to date on the use of autologous adipose-derived and bone marrow-derived mesenchymal stem cells at the point of care utilizing the stromal vascular fraction for the treatment of arthritis will be provided.  The use of autologous mesenchymal culture expanded cells (bone marrow and adipose derived) in the treatment of osteoarthritis will be reviewed, as well as the use of allogeneic mesenchymal cells in osteoarthritis and rheumatoid arthritis treatments. Finally, the prospect of cryopreservation, cell banking, and culture expansion of mesenchymal stem cells will  be discussed.


Rehealth offers high-quality cellular therapy for many diseases. Find out if you’re a candidate for our stem cell therapies.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *